Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Heart Transplant Recipients
NCT06625073Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart transplantation, cardiovascular disease (CVD) and Kidney disease comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Urinary albumin-to-creatinine ratio at 12 months and Incidence of Treatment-Emergent Adverse Events at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart transplantationcardiovascular disease (CVD)Kidney disease
Beyond the preview
Go deeper on NCT06625073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625073.